Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1J01GB01----[1] 299
2J05A F01----[1] 135
3J05AG04----[1] 18
4J07AH07----[1] 14
5J1081----[1] 56
6J695----[1] 96
7J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0----[1] 96
8JAK 3----[1] 46
9JAK 3 Ritlecitinib----[1] 46
10JAK inhibitor----[2] 46, 50
11JAK1 / JAK2 Inhibitor----[1] 46
12JAK1 / JAK2 Inhibtor----[1] 46
13JAKi----[1] 46
14Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets[1] Acetylcysteine[1] D00221 --[1] 85
15Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets[1] Acetylcysteine[1] D00221 --[1] 85
16Jaktinib Hydrochloride Tablets----[1] 271
17Janus Kinase Inhibitor----[2] 46, 97
18Jardiance[1] Empagliflozin[1] D10459 [1] SLC5A2 💬-[1] 65
19JBT-101----[4] 49, 50, 51, 299
20JBT-101 (lenabasum)----[1] 299
21JBT101----[1] 299
22Jevity 1.0----[1] 2
23Jevity 1.5----[1] 2
24JHL1101----[1] 46
25Jianpixiaozhong particles and Wuse Dietotherapy----[1] 222
26Jinarc[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
27JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG)[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
28JINARC - 15 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
29JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG)[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
30JINARC - 30 MG +90 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 90 MG)[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
31JINARC - 30 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
32Jinarc - Tolvaptan tablets[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
33Jinarc 15 mg tablets, Jinarc 45 mg tablets[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
34Jinarc 30 mg Tablet[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
35Jinarc 30 mg tablets, 90 mg tablets[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
36Jinarc 30 mg tablets, Jinarc 60 mg tablets[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
37Jinarc® 15mg Tablet[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
38Jinarc® 30 Tablet[1] Tolvaptan[1] D01213 [1] AVPR2 💬[3] Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬[1] 67
39Jintropin AQ----[1] 78
40JKB-122----[1] 95
41JKB-122 in capsule or tablet form----[1] 95
42JM----[2] 6, 13
43JM-010----[1] 6
44JM-4----[1] 13
45JNJ 38518168----[1] 46
46JnJ 54767414----[1] 28
47JNJ-16240159-AAC----[1] 46
48JNJ-31001074----[1] 6
49JNJ-38518168----[1] 46
50JNJ-38518168 (10 mg)----[1] 46
51JNJ-38518168 (3 mg)----[1] 46
52JNJ-38518168 (30 mg)----[1] 46
53JNJ-38518168 / MTX----[1] 46
54JNJ-38518168 50-mg Over Encapsulated Tablet----[1] 46
55JNJ-38518168-AEK - Over Encapsulated Tablet - 50 mg----[1] 46
56JNJ-38518168-ZBQ----[1] 46
57JNJ-38518168-ZBQ - film-coated tablet - 10 mg----[1] 46
58JNJ-38518168-ZBQ - film-coated tablet - 10mg----[1] 46
59JNJ-38518168-ZBQ - film-coated tablet - 3 mg----[1] 46
60JNJ-38518168-ZBQ - film-coated tablet - 30 mg----[1] 46
61JNJ-38518168-ZBQ - film-coated tablet - 30mg----[1] 46
62JNJ-38518168-ZBQ - film-coated tablet - 3mg----[1] 46
63JNJ-39039039----[1] 210
64JNJ-39758979----[1] 46
65JNJ-39758979 (10 mg)----[1] 46
66JNJ-39758979 (100 mg)----[1] 46
67JNJ-39758979 (30 mg)----[1] 46
68JNJ-39758979 (300 mg)----[1] 46
69JNJ-39758979 / MTX----[1] 46
70JNJ-39758979-AAC - enteric coated tablet - 10 mg----[1] 46
71JNJ-39758979-AAC - enteric coated tablet - 100 mg----[1] 46
72JNJ-39758979-AAC - enteric coated tablet - 30 mg----[1] 46
73JNJ-40346527[1] JNJ-40346527---[2] 46, 96
74JNJ-40346527-AAC[1] JNJ-40346527---[1] 96
75JNJ-40346527-AAC - capsule - 50 mg[1] JNJ-40346527---[1] 46
76JNJ-42160443----[1] 226
77JNJ-54767414----[2] 28, 49
78JNJ-54781532 150 mg once daily----[1] 97
79JNJ-54781532 25 mg once daily----[1] 97
80JNJ-54781532 75 mg once daily----[1] 97
81JNJ-54781532 75 mg twice daily----[1] 97
82JNJ-54781532-AAD-10 mg----[1] 97
83JNJ-54781532-AAD-30 mg----[1] 97
84JNJ-54781532-AAD-5 mg----[1] 97
85JNJ-55920839----[1] 49
86JNJ-56022473----[1] 49
87JNJ-64304500----[1] 96
88JNJ-64304500-AAA----[1] 96
89JNJ-64841829----[1] 97
90JNJ-64841842----[1] 97
91JNJ-64841855----[1] 97
92JNJ-64841894----[1] 97
93JNJ-64841907----[1] 97
94JNJ-64841920----[1] 97
95JNJ-64841933----[1] 97
96JNJ-64841946----[1] 97
97JNJ-66525433----[1] 97
98JNJ-67484703----[1] 46
99JNJ-67864238----[1] 96
100JNJ-67896049----[1] 86
101JNJ-67896049 (ACT-293987)----[1] 86
102JNJ-67896062 / ACT-064992----[2] 86, 88
103JNJ-67896062/ ACT-064992----[2] 86, 88
104JNJ-67896062/ACT-064922----[1] 86
105JNJ-67896153/ACT-128800----[1] 13
106JNJ-72537634----[1] 97
107JNJ-78934804----[2] 96, 97
108JNJ-80202135----[4] 11, 46, 49, 53
109JNJ31-31001074----[1] 6
110Joint puncture----[1] 107
111Jojoba oil[1] Jojoba oil---[1] 36
112Jojoba oil with broccoli sprout extract[2] Broccoli,
Jojoba oil		---[1] 36
113Jorveza[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
114Jorveza 0.5 mg compresse orodispersibili[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
115Jorveza 0.5 mg orodispersible tablets[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
116Jorveza 1 mg compresse orodispersibili[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
117Jorveza 1 mg orodispersible tablets[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
118JP 1730----[1] 6
119JP-1730/F01----[2] 6, 17
120JP-1730/F02----[2] 6, 17
121JP-1730/F03----[2] 6, 17
122JR-141----[1] 19
123JR-141 or Idursulfase[1] Idursulfase[1] D04499 [1] IDS 💬[3] Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬[1] 19
124JR-171 (lepunafusp alfa)----[1] 19
125JS002----[1] 79
126JS005----[1] 271
127JSP191----[2] 65, 285
128JTE-051----[1] 46
129JTT-251----[1] 86
130Juanbi pill----[1] 46
131Juvit D3----[1] 6
132Jyseleca[1] Filgotinib[1] D10871 [1] JAK1 💬[27] Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬[1] 46
133Jyseleca 100 mg film-coated tablets[1] Filgotinib[1] D10871 [1] JAK1 💬[27] Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬[1] 46
134Jyseleca 200 mg film-coated tablets[1] Filgotinib[1] D10871 [1] JAK1 💬[27] Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬[1] 46
135JZP-110----[1] 6